Mesenchymal Stromal Cells Mediate Clinically Unpromising but Favourable Immune Responses in Kidney Transplant Patients

Figure 1

Treatment scheme for KTx patients recruited for the study. MSCs were isolated from bone marrow aspirate and expanded for 60 days (D-60) before transplantation. All KTx patients received immunosuppressive drugs (tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisolone) 48 hours before transplantation (D-1). Allo and auto group patients received the 1^st intravenous (I.V.) MSC infusion 24 hours before transplantation (D-0) and the 2^nd I.V. MSC infusion 30 days posttransplantation (D-30). Blood samples were collected at D-0, D-30, D-90, D-180, D-365, and D-800 for determining clinical and immunological parameters. Samples were routinely processed for serum creatinine estimation.